Group 1 - Pfizer has accelerated the development of SSGJ-707 (PF-4404) with plans to initiate at least 7 clinical trials, including two global Phase III trials starting in December targeting 1L sq-/nsq-NSCLC and metastatic colorectal cancer [1] - The company aims to expand SSGJ-707 into over 10 new indications and more than 10 new combination therapies by the end of 2026, including evaluating its use with Pfizer's extensive ADC product portfolio [1] - Pfizer has identified over 500 clinical centers across more than 25 countries for the development of PF-4404 and has completed domestic production in the U.S. to ensure efficient development and compliance with global registration requirements [1] Group 2 - The company plans to spin off its consumer pharmaceutical business, Mandi International, for a listing on the Hong Kong Stock Exchange, which will allow it to focus on prescription and innovative drugs [2] - The spin-off is expected to generate short-term investment returns and support the commercialization of new products after the separation [2] - The target price for the stock has been raised to 39.5 HKD due to strong clinical data and partner support, reflecting increased confidence in the global development of SSGJ-707 [2]
三生制药(1530.HK)：707海外开发快速推进 蔓迪计划分拆聚焦创新主业；上调目标价